Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors

Clinical trial NCT05764395 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05764395
Sponsor: Vanderbilt-Ingram Cancer Center
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Clinical Stage III Cutaneous Melanoma AJCC v8 Clinical Stage IV Cutaneous Melanoma AJCC v8 Metastatic Melanoma Refractory Melanoma Unresectable Melanoma

Start date: 2023-05-09
Primary completion: 2028-05-01
Enrollment: 7

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.